Trial Profile
Pharmacodynamic Interaction between TAK-442, an Oral Direct Factor Xa Inhibitor, and Prasugrel in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2011
Price :
$35
*
At a glance
- Drugs Letaxaban (Primary) ; Prasugrel
- Indications Acute coronary syndromes; Sickle cell anaemia; Thromboembolism
- Focus Pharmacodynamics
- 20 Apr 2011 New trial record